![Robin Stevenson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robin Stevenson
Director/Board Member at Avelas Biosciences, Inc.
Robin Stevenson active positions
Companies | Position | Start | End |
---|---|---|---|
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Director/Board Member | 17/10/2021 | - |
Career history of Robin Stevenson
Former positions of Robin Stevenson
Companies | Position | Start | End |
---|---|---|---|
The Breast Cancer Research Trust
![]() The Breast Cancer Research Trust Medical SpecialtiesHealth Technology The Breast Cancer Research Trust operates as not-for profit organization. It provides breast cancer treatment solutions. The company was founded in 1997 and is headquartered in Auckland, New Zealand. | Director/Board Member | - | - |
Statistics
International
New Zealand | 2 |
United States | 2 |
Operational
Director/Board Member | 2 |
Sectoral
Health Technology | 2 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
The Breast Cancer Research Trust
![]() The Breast Cancer Research Trust Medical SpecialtiesHealth Technology The Breast Cancer Research Trust operates as not-for profit organization. It provides breast cancer treatment solutions. The company was founded in 1997 and is headquartered in Auckland, New Zealand. | Health Technology |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
- Stock Market
- Insiders
- Robin Stevenson
- Experience